Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir

HIV Medicine

Volumn 13, Issue 9, 2012, Pages 558-563

  Bech, A ^a   Van Bentum, P ^a   Nabbe, K ^a   Gisolf, J ^a   Richter, C ^a   De Boer, H ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Fibroblast growth factor 23; HIV; Hypophosphataemia; Tenofovir

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CALCIUM METABOLISM; CLINICAL ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY TUBULE ABSORPTION; MALE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL;

ADENINE; ANTI-HIV AGENTS; CALCIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HIV SEROPOSITIVITY; HUMANS; HYPOPHOSPHATEMIA; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PARATHYROID HORMONE-RELATED PROTEIN; PHOSPHATES;

EID: 84866154768     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01015.x     Document Type: Article

References (20)

1. Buchacz K, Brooks JT, Tong T etal. Evaluation of hypophosphatemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med 2006; 7: 451-456.
2. Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect 2006; 52: 335-358.
3. Paccou J, Viget N, Legrout-Gerot I, Yazdanpanah Y, Cortet B. Bone loss in patients with HIV infection. Joint Bone Spine 2009; 76: 637-641.
4. Mc Comsey G. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. HIV/AIDS 2010; 51: 937-946.
5. Madeddu G, Solinas P, Calia GM, Lovigu C. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004; 48: 39-48.
6. Welz T, Childs K, Ibrahim F etal. Efavirenz is asscoiated with severe vitamin D deficiency and increased alkaline phophatase. AIDS 2010; 24: 1923-1928.
7. Mueller N, Fux C, Ledergerber B etal. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and succesfully treated Swiss patients. AIDS 2010; 24: 1127-1134.
8. Wanner DP, Tyndall A, Walker UA. Tenofovir-induced osteomalacia. Clin Exp Rheumatol 2009; 27: 1001-1003.
9. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773-780.
10. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004; 19: 714-721.
11. Nelson MR, Katlama C, Montaner JS etal. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21: 1273-1281.
12. Fukumoto S. Physiological regulation and disorders of phosphate metabolism pivote role of fibroblast growth factor 23. Int Med 2008; 47: 337-343.
13. Vervloet MG, Ittersum FJ, Buttler RM, Heijboer A, Blankenstein MA, ter Wee PM. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011; 2: 383-389.
14. Quarles L. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008; 118: 3820-3828.
15. Kemp GJ, Blumsohn A, Morris BW. Circadian changes in plasma phosphate concentration, urinary phosphate excretion, and cellular phosphate shifts. Clin Chem 1992; 38: 400-402.
16. Bijvoet OL. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci 1969; 37: 23-36.
17. Kemperman FA, Krediet RT, Arisz L. Formula-derived prediction of the glomerular filtration rate from plasma creatinine concentration. Nephron 2002; 91: 547-558.
18. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010; 394: 48-53.
19. Paccou J, Viget N, Legrout-Gérot I, Yazdanpanah Y, Cortet B. Bone loss in patients with HIV infection. Joint Bone Spine 2009; 76: 637-641.
20. Bout-Van Den Beukel CJ, Fievez L, Michels M etal. Vitamin D deficiency among HIV type1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 1375-1382.